RADX (Radiopharm Theranostics Limited American Depositary Shares) Stock Analysis - Analyst Ratings

Radiopharm Theranostics Limited American Depositary Shares (RADX) is a publicly traded Healthcare sector company. As of May 21, 2026, RADX trades at $4.58 with a market cap of $37.45M and a P/E ratio of 0.00. RADX moved -0.22% today. Year to date, RADX is -10.20%; over the trailing twelve months it is +4.09%. Its 52-week range spans $3.50 to $50.82. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces RADX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate RADX?

2 analysts cover RADX: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $22.50.

RADX Key Metrics

Key financial metrics for RADX
MetricValue
Price$4.58
Market Cap$37.45M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$50.82
52-Week Low$3.50
Volume12
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

RADX Analyst Consensus

2 analysts cover RADX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.

Latest RADX News

Common questions about RADX

What do analysts rate RADX?
2 analysts cover RADX: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $22.50.
Does Rallies show RADX price targets?
Yes. Rallies tracks RADX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is RADX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RADX. It does not provide personalized investment advice.
RADX

RADX